Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CT-G20 and CT-G11 in Healthy Volunteers
NCT03918967Phase 1Completed
- Sponsor
- Celltrion
- Start
- Apr 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Cibenzoline S-isomer and CT-G11 in hypertrophic cardiomyopathy (HCM) (4 arms), sponsored by Celltrion. Primary endpoints: Incidence of Adverse events including serious Adverse events at 46 days, Area under the concentration-time curve up to 48 hours and 1 more. Started Apr 2019; status: completed.
02
Drugs
Cibenzoline S-isomerCT-G11
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT03918967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03918967.